Merger Announced
Indivior Pharmaceuticals and Supernus Pharmaceuticals merger
Announced 3 Aug 2026 · NASDAQ: SUPN
Advisers
Supernus Pharmaceuticals
Target
- Financial adviser
- Legal adviser
- Fairness opinion
Acquirer
- Financial adviser
- Legal adviser
- Fairness opinion
Other advisers
- Legal adviser
- Target
- Supernus Pharmaceuticals
- Target based in
- United States
- Sector
- Pharma
In the league tables
- M&A financial advisers, 2026 to date Citi #7 · Wells Fargo Securities #8 · Jefferies #14 · Piper Sandler #22 · Cantor Fitzgerald #39
- M&A legal advisers, 2026 to date Goodwin #12 · Morgan Lewis #35 · Saul Ewing #237
- Fairness opinion providers, 2026 to date Jefferies #5 · Piper Sandler #10 · Cantor Fitzgerald #32
Similar deals
- Fresenius acquisition of mAbxience Oct 2026 · US$1.9bn · Biotech
- Gilead acquisition of HCXT-2001 (investigational oral IL-23R inhibitor) Oct 2026 · Pharma
- US WorldMeds acquisition of Orbus Therapeutics Oct 2026 · Pharma
- DRI Healthcare Trust acquisition of Royalty participation rights in U.S. net sales of tavapadon Sep 2026 · US$316m · Specialty finance and leasing
- Grünenthal acquisition of Stivarga (regorafenib) Sep 2026 · US$433m · Pharma
Sources
- 3 Aug 2026 Press release (EX-99.1, exhibit), Pursuant to Rule 425 under the Securities sec.gov
- 3 Aug 2026 Press release (EX-99.3, exhibit), Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS sec.gov
- 13 Aug 2026 Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals morganlewis.com
- 11 Sep 2026 Definitive merger proxy statement (DEFM14A), SUPERNUS PHARMACEUTICALS, INC. sec.gov





